Menu
Fechar
hrs4r
 I want to donate

The Haematology research group at the IDIBGI started in 2007 as an extension of the haematology service at ICO Girona. The group is dedicated to clinical and translational studies in relation to diagnostic, prognostic, and therapeutic processes in hemopathies, the group is made up of haematologists, nurses, biologists and technicians.

Main lines of research
  • Study genetic variants involved in the immune response as survival predictors and graft disease against the host after allogenic transplantation of hematopoietic progenitors.
  • Study biological and pharmacogenomic aspects associated with response to the treatment of acute myeloblastic leukaemia
  • Analysis of genetic polymorphisms as predictors of multiple myeloma progression.
  • Study of genetic polymorphisms involved in evolution and the response to treatment of chronic lymphatic leukaemia.
  • Study of cell populations using flow cytometry for the characterization of hemopathies and detection of residual disease.
Strategic objectives
  • To investigate biological, clinical, and epidemiological aspects of haematological diseases
  • To carry out translational research projects focused on finding prognostic factors or treatment response predictors
  • To carry out clinical research, promoting participation in clinical trials for haematological diseases and participating in national or international cooperative groups.
Publications
Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin-Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, Campo E

BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases

Haematologica, 2024, 109, 493-508 dx.doi.org/10.3324/haematol.2023.283209
Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Haematologica, 2024, 109, 543-552 dx.doi.org/10.3324/haematol.2023.283342
Muñoz NG, Ortega S, Solanich X, Cid J, Díaz M, Moreno AB, Ancochea Á, Santos M, Hernández I, Sanchez JM, Luaña A, García J, Escoda L, Medina L, Ferrer GJ, López J, Céspedes R, Díaz JA, Pons V, Valcárcel D, Grifols JR

Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group.

BLOOD TRANSFUSION, 2024, 22, 176-184 dx.doi.org/10.2450/BloodTransfus.522
Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, Paiva B, Cedena MT, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, González E, Casado LF, Martí JM, Encinas C, De Arriba F, Palomera L, Sampol A, González-Montes Y, Motlló C, De La Cruz J, Alonso R, Mateos MV, Bladé J, Lahuerta JJ, San-Miguel J, Hernández MT

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Haematologica, 2024, 109, 1909-1917 dx.doi.org/10.3324/haematol.2023.284154
Hernández-Sánchez A, Villaverde-Ramiro Á, Arellano-Rodrigo E, Garrote M, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Ferrer-Marín F, Such E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, de Villambrosía SG, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín A, Raya JM, González JA, Cuevas B, Xicoy B, Pérez-Encinas M, Bellosillo B, Álvarez-Larrán A, Hernández-Rivas JM, Hernández-Boluda JC, Spanish MPN Group (GEMFIN)

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99, 755-758 dx.doi.org/10.1002/ajh.27203
González-Calle V, Rodríguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, González-Rodríguez AP, González Y, Oriol A, Martínez-López J, González MS, Hernández MT, Sirvent M, Cedena T, Puig N, Paiva B, Bladé J, Lahuerta JJ, San-Miguel JF, Mateos MV

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.

Haematologica, 2024, 109, 2219-2228 dx.doi.org/10.3324/haematol.2023.284089
Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L, Grupo Español de Leucemia Mieloide Crónica (GELMC)

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

Journal of Clinical Medicine, 2024, 13 dx.doi.org/10.3390/jcm13030779
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J

Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (vol 12, 13057, 2022)

SCIENTIFIC REPORTS, 2024, 14, 7400-7400 dx.doi.org/10.1038/s41598-024-57570-5
Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R, Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M

Identification of novel NUP98 fusion partners and co-mutations in Acute Myeloid Leukemia: an adult cohort study.

Blood Advances, 2024, 8, 2691-2694 dx.doi.org/10.1182/bloodadvances.2023012479
Mosquera-Orgueira A, Arellano-Rodrigo E, Garrote M, Martín I, Pérez-Encinas M, Gómez-Casares MT, Hernández-Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, Heras NL, Magro E, Pérez-Míguez C, Crucitti D, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Nangalia J, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

HemaSphere, 2024, 8 dx.doi.org/10.1002/hem3.60
Competitive projects
Haematology

Genotipo de las moléculas inhibidoras de respuesta inmune: más allá del trasplante alogénico. Banco nacional de ADN de pacientes tratados con terapia CAR-T.

Codi oficial: PI20/01353 Start date:01/01/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III
Haematology

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Hematologia

Codi oficial: 6822ZB3KJ Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA (AGAUR)
Haematology

Relevancia del genotipo de LAG3 y moléculas checkpoint en el trasplante alogénico de progenitores hematopyéticos.

Codi oficial: Projecte IJC - Dr. David Gallardo Start date:01/07/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS
Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

 menu